Fortrea Holdings Inc. (FTRE) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash generation ⢠Heavy net losses ⢠Tight liquidity FTRE generates strong cash flow and trades below tangible book, but its heavy losses, high leverage, and weak liquidity make the investment case highly risky.
Price Behavior
Key Price Behavior Insights: ⢠Choppy rebound ⢠Tight resistance ⢠Support holding Support Level: $9.00-$9.60 Resistance Level: $10.50-$10.60 FTRE has improved over the last month and repeatedly found support around $9.00â$9.60, but the failed breakout near $10.50 suggests the short-term uptrend is still fragile unless it can hold above that resistance.
Sentiment & News
Key News Insights: ⢠AI platform launch ⢠Q1 earnings date ⢠Mixed ownership flow Fortrea is advancing its clinical-trial technology with a new AI-powered suite while also providing routine earnings timing and mixed investor ownership updates.
AI Summary
FTRE is now best viewed as a cash-generating turnaround with a real commercial recovery, but the stock likely won't re-rate unless improving win rates and backlog translate into higher-quality service-fee growth and sustained EBITDA expansion rather than pass-through-heavy revenue, especially with leverage still limiting flexibility.
Description
Fortrea Holdings Inc. is a contract research organization that provides development services for biopharmaceuticals and medical devices globally. Its operations are organized into Clinical Services, covering clinical pharmacology and the spectrum of clinical development, and Enabling Services, which supplies patient access, trial technology, randomization and drug supply support. The company delivers these capabilities through full-service, functional service provider and hybrid models and also offers phase IâIV trial management and post-approval support; it was incorporated in 2023 and is based in Durham, North Carolina.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 4 | Dec 11 | FTRE | Fortrea Holdings Inc. | Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management. | Closed | +7.2% |